- Secukinumab is associated with sustained skin clearance and QoL in patients with moderate to severe psoriasis, according to results from an open-label extension of the phase 3b CLEAR study.
Why this matters
- Initial analysis of CLEAR had demonstrated superior efficacy for secukinumab vs ustekinumab (Stelara); this study demonstrated sustained long-term efficacy.
- At 2 years, secukinumab was associated with:
- 89.6% of patients achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI 75).
- 74.7% achieving PASI 90.
- 47.4% achieving PASI 100.
- 68.8% achieving Investigator’s Global Assessment 2011 modified version 0/1.
- 66.0% achieving Dermatology Life Quality Index 0/1 (as-observed analysis).
- Secukinumab was also associated with complete relief for pain, itching, and scaling in 70.9%, 47.4%, and 54.8% of patients, respectively, at 2 years (as-observed analysis).
- Candida infection was reported in 7.2% of patients, whereas malignant or unspecified tumors were reported in 1.5% of patients.
- 277 patients randomly assigned to receive secukinumab 300 mg from the original CLEAR cohort completed the 2-year extension.
- Funding: Novartis Pharma AG.
- Open-label trial.